HIMS to Introduce Compounded GLP-1 Injections, What Plan Sponsors Need to Know Scripta May 28, 2024 3 min read Updated: Jun 14, 2024 Hims & Hers' (HIMS) latest move to introduce compounded GLP-1 injections into its weight loss program is stirring up excitement and raising a few eyebrows among plan sponsors
doi: 10.1016/j.jdiacomp.2014.10.001 117 ZhaoLWangHXieJChenZLiXNiuJ
Dont let high prices hold you back from reaching your weight loss goals
However, these adjusted thresholds have not been formally incorporated into FDA labeling for GLP-1 medications, creating a significant gap where Asian patients may have clear metabolic indications for treatment but fail to meet the standard BMI criteria
Between 20% and 50% of semaglutide users experience nausea, and slow titration has been shown to reduce that rate by approximately 30%
You may experience bleeding in your retina, swelling, or growth of abnormal blood vessels during this time